Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma

Core Evidence

Volumn 6, Issue , 2011, Pages 43-57

  Jain, Salvia ^a   Diefenbach, Catherine ^a   Zain, Jasmine ^a   O'Connor, Owen A ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carfilzomib; Efficacy; Multiple myeloma; Pharmacology; Safety

Indexed keywords

BORTEZOMIB; CARFILZOMIB; SALINOSPORAMIDE A; VORINOSTAT;

ANEMIA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER RECURRENCE; COLORECTAL CANCER; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HEALTH CARE COST; HODGKIN DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL EDEMA; PHARMACODYNAMICS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

EID: 83655198773     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S13838     Document Type: Review

References (78)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520.
2. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia. 2009;23:1152-1157.
3. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
4. Richardson PG, Barlogie B, Berenson J, et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348: 2609-2617.
5. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or highdose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
6. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050-4053.
7. Richardson PG, Blood E, Mitsiades CS, et al. A randomized Phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458-3464.
8. Fuchs D, Berges C, Opelz G, et al. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem. 2008;103:270-283.
9. Ruckrich T, Kraus M, Gogel J, et al. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia. 2009;23:1098-1105.
10. Lu S, Chen Z, Yang J, et al. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol. 2008;36:1278-1284.
11. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: Proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112:2489-2499.
12. Lu S, Yang J, Song X, et al. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther. 2008;326:423-431.
13. Moreau P, Pylpenko H, Grosicki S, et al. A Phase 3 prospective randomized international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma. Blood. 2010;116:141.
14. Demo SD, Kirk CJ, Aujay MA, et al. Anti-tumor activity of PR-171, a novel irreversible inhibitor of the proteosome. Cancer Res. 2007;67: 6383-6391.
15. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer. 2004;4:349-360.
16. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res. 2008;14:1649-1657.
17. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008;11:164-179.
18. SterzJ, Hahne JC, Lamottke B, et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs. 2008;17: 879-895.
19. Adams J. The proteasome: Structure, function, and role in the cell. Cancer Treat Rev. 2003;29 Suppl:3-9.
20. Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem. 2006;281:8582-8590.
21. Bennett MK, Kirk CJ. Development of proteasome inhibitors in oncology and autoimmune diseases. Current Opin Drug Discov Devel. 2008; 11:616-625.
22. Altun M, Galardy PJ, Shringarpure R, et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 2005;65:7896-7901.
23. Groll M, Kim KB, Kairies N, et al. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis of α1, β1-epoxyketone proteasome inhibitors. J Am Chem Soc. 2000;122:1237-1238.
24. Groll M, Huber R, Potts BC. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc. 2006;128:5136-5141.
25. Demo SD, Buchholz TJ, Laidig GJ, et al. Biochemical and cellular characterization of the novel proteasome inhibitor PR-171. Blood. 2005;106:Abstr 1588.
26. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorg Med Chem Lett. 1998;8: 333-338.
27. Dorsey BD, Iqbal M, Chatterjee S, et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem. 2008;51:1068-1072.
28. Parlati F, Lee S, Aujay, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009;114:3439-3447.
29. Kuhn DJ, Chen Q, Voorhees, et al. Potent activity of carfilzomib, a novel irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281-3290.
30. Suzuki E, Demo S, Arastu-Kapur S, et al. Bortezomib resistant cell lines have increased proteasome levels but remain sensitive to carfilzomib. Blood. 2009;114:Abstr 2852.
31. Wang L, Kumar S, Fridley BL, et al. Proteasome β subunit pharmacogenomics: Gene resequencing and functional genomics. Clin Cancer Res. 2008;14:3503.
32. Trudel S, Lee S, Kirk CJ, et al. Inhibition of the proteasome in bone marrow derived CD138+ tumor cells following carfilzomib administration in relapsed and refractory myeloma patients. Blood. 2009;114:Abstr 1845.
33. Stapnes C, Doskeland A, Hatfield K, et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukemia cells. Br J Haematol. 2007;136:814-828.
34. Dasmahapatra G, Lembersky D, Kramer L, et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 2003;115:4478-4487.
35. Rao R, Fiskus W, Balusu R, et al. Treatment with histone deacetylase-6 inhibitor WT-161 disrupts hsp-90 function, abrogates aggresome formation and sensitizes human mantle cell lymphoma cells to lethal ER stress induced by proteasome inhibitor carfilzomib. Blood. 2010;116:Abstr 2856.
36. Kirk CJ, Benett MK, Buchholz TJ, et al. Pharmacokinetics, pharmacodynamics and anti-tumor efficacy of PR-171, a novel inhibitor of the 20S proteasome. Blood. 2005;106:Abstr 609.
37. O'Connor OA, Stewart AK, Vallone M, et al. A Phase I dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009;15:7085-7091.
38. Rosen PJ, Gordon M, Lee PN, et al. Phase II results of Study PX-171-007: A Phase Ib/II study of carfilzomib, a selective proteasome inhibitor in patients with selected advanced metastatic solid tumors. J Clin Oncol. 2009;27 Suppl:3515.
39. Lee P, Wong AF, Burris HA, et al. Updated results of a Phase Ib/II study of carfilzomib in patients with relapsed malignancies. J Clin Oncol. 2010;28(15Suppl):8147.
40. Alsina M, Trudel S, Vallone M, et al. Phase I single agent antitumor activity of twice weekly consecutive dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood. 2007;110:Abstr 411.
41. Jagannath S, Vij R, Stewart K, et al. Final results of PX-171-003-A0, part 1 of an open label, single arm, Phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma. J Clin Oncol. 2009;27(15 Suppl):8504.
42. Siegel DS, Martin T, Wang M, et al. Results of PX-171-003-A1, an open label, single arm, Phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma. Blood. 2010;116: Abstr 985.
43. Vij R, Wang M, Orlowski R, et al. PX-171-004, a multicenter Phase II study of carfilzomib in patients with relapsed myeloma: An efficacy update. J Clin Oncol. 2009;27(15 Suppl):8537.
44. Wang L, Siegel D, Kaufman JL, et al. Updated results of bortezomibnaïve patients in PX-171-004, an ongoing open label, Phase II study of single agent carfilzomib in patients with relapsed or refractory MM. Blood. 2009;114:Abstr 302.
45. Siegel D, Wang L, Orlowski RZ, et al. PX-171-004, an ongoing open label Phase II study of single agent carfilzomib in patients with relapsed or refractory MM; updated results from the bortezomib treated cohort. Blood. 2009;114:Abstr 303.
46. Vij R, Siegel DS, Kaufman JL, et al. Results of an ongoing open label, Phase II study of carfilzomib in patients with relapsed and/or refractory MM. J Clin Oncol. 2010;28(15 Suppl):8000.
47. Jakubowiak A, Wang L, Orloski R, et al. Influence of cytogenetics in patients with relapsed and refractory multiple myeloma treated with carfilzomib. Blood. 2009;114:Abstr 1827.
48. Niesvizky R, Bensinger W, Vallone M, et al. PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low-dose dexamethasone in relapsed and refractory MM: Preliminary results. J Clin Oncol. 2009;27(15 Suppl):8514.
49. Bensinger W, Wang M, Orlowski RZ, et al. Dose escalation study of carfilzomib plus lenalidomide plus low-dose dexamethasone in relapsed and refractory MM. J Clin Oncol. 2010;28(15 Suppl):8029.
50. Alsayed Y, Nair BP, Kauffman M, et al. Carfilzomib in combination with Dex and other agents (Dox, thal, DDP, vorinostat ) for far advanced and refractory multiple myeloma (FARMM). J Clin Oncol. 2010;28(15 Suppl):e18504
51. Badros A, Vij R, Martin T, et al. Phase I study of carfilzomib in patients with relapsed and refractory multiple myeloma and varying degrees of renal insufficiency. Blood. 2009;114:Abstr 3877.
52. Badros A, Vij R, Martin T, et al. Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency. J Clin Oncol. 2010;28(15 Suppl):8128.
53. Vij R, Wang L, Orlowski, et al. Carfilzomib, a novel proteasome inhibitor for relapsed or refractory multiple myeloma, is associated with minimal peripheral neuropathic effects. Blood. 2009;114:Abstr 430.
54. Wolf JL, Vij R, Lonial S, et al. Neurotoxic and peripheral neuropathic beffects in preclinical and clinical studies of carfilzomib, a novel proteasome inhibitor. J Clin Oncol. 2010;28(15 Suppl):8135.
55. Kuhn DJ, Hunsucker SA, Voorhees PM, et al. Targeted inhibition of the proteasome is a potent strategy against models of myeloma that overcome resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2009;113:4667-4676.
56. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:667-675.
57. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676-684.
58. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006;24:2105-2112.
59. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter Phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867-4874.
60. Belch A, Kouroukis CT, Crump M, et al. A Phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol. 2007;18:116-121.
61. Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol. 2009;146:652-655.
62. Berenson JR, Yang HH, Vescio RA, et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: Updated results of a Phase 1/2 study after longer follow-up. Ann Hematol. 2008;87:623-631.
63. Popat R, Oakervee H, Williams C, et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol. 2009;144:887-894.
64. Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia. 2008;22:1419-1427.
65. Reece DE, Piza G, Trudel S, et al. A Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone for relapsed/refractory multiple myeloma. Blood. 2006;108:Abstr 3536.
66. Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138:330-337.
67. Hajek R, Zahradova L, Gregora E, et al. The reduced intensity CVD regimen: A good option with well-balanced efficacy/toxicity ratio for elderly patients with poor status performance. Blood. 2008;112:Abstr 3699.
68. Lee SS, Suh C, Kim BS, et al. Bortezomib, doxorubicin and dexamethasone (PAD) combination therapy followed by thalidomide and dexamethasone (TD) as a salvage treatment for relapsed multiple myeloma (MM): Preliminary analysis of efficacy and safety. Blood. 2007;110:Abstr 2731.
69. Palumbo A, Gay F, Bringhen S, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol. 2008;19: 1160-1165.
70. Richardson P, Jagannath S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): Encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a Phase II study. Blood. 2008;112:Abstr 1742.
71. Poenisch W, Bourgeois M, Wang SY, et al. Bortezomib in combination with bendamustine and prednisone in the treatment of patients with refractory/relapsed multiple myeloma. Blood. 2007;110: Abstr 2723.
72. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767-2772.
73. Terpos E, Heath DJ, Zervas K, Dimopoulos MA. The effect of bortezomib monotherapy and bortezomib-based regimens on bone metabolism in patients with relapsed/refractory multiple myeloma. Paper presented at: Haematologica. 2007;92:133 (PO320). [4th International Workshop on Waldenstrom's macroglobulinaemia. Kos, Greece, 25-30/6/2007].
74. Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol. 2008;141:814-819.
75. Kim YK, Lee JJ, Sohn SK, et al. Clinical efficacy of VEL-CTD (bortezomib, cyclophosphamide, thalidomide, and dexamethasone) regimen in patients with relapsed or refractory multiple myeloma: A Phase II study. Blood. 2008;112:Abstr 3693.
76. Zangari M, Polavaram L, Zhan F, et al. Alkaline phosphatase variation during carfilzomib treatment is associated to best response in multiple myeloma. Blood. 2009;114:Abstr 2895.
77. Chen Q, Xie W, Kuhn DJ, et al. Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood. 2008;111:4690-4699.
78. Richardson PG, Hofmeister C, Jakubowiak A, et al. Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (MM). Blood. 2009;114:Abstr 431.